TOKYO - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter 'ASKA') and Harbin Pharmaceutical Group Co., Ltd. (Heilongjiang Province, China, CEO: Helen Chui, hereinafter 'Hayao') signed an Exclusive License Agreement in China for the H2 receptor antagonist ALTAT (generic name: Roxatidine Acetate Hydrochloride, dosage form: Injection, Capsule, Fine Granules) developed and sold by ASKA.

Business Rationale for the Agreement

With the conclusion of this agreement, ASKA will receive an upfront payment from Hayao and the right to receive royalties according to sales, in exchange for granting the exclusive sales right of ALTAT in China.

Aiming for the continuous growth and development of our company through the development of overseas business, the International Business Division was established in April 2020 and started its activities in earnest. With this agreement as one of the footholds, we will further accelerate business development in the Asian region

Contact:

Tel: +81-3-5484-8361

(C) 2021 Electronic News Publishing, source ENP Newswire